Description of the blood test:

Anti-centromere antibodies (ACA) are autoantibodies that target the centromeres of chromosomes—the specialized regions that hold sister chromatids together during cell division. While Sci-70 is linked to the diffuse form of scleroderma, ACA is the primary marker for Limited Cutaneous Systemic Sclerosis, formerly known as CREST Syndrome. This condition is generally more slow-moving and primarily affects the skin of the hands, face, and feet, rather than the entire body.

What Does the Test Represent?

• Goal: To detect IgG antibodies against centromere proteins (CENP-A, CENP-B).
• Main Application: Diagnosing Limited Systemic Sclerosis and distinguishing it from other autoimmune diseases.
• Method: Indirect Immunofluorescence (IIF) — usually showing a characteristic “speckled” or “punctate” pattern on HEp-2 cells.

Collection Recommendations (General)

• Timing: Standard morning collection.
• Fasting: Fasting for 8–12 hours is recommended; plain water is allowed.
• Material: Venous blood (serum).
• Specific Rules: Inform your doctor if you experience the “CREST” symptoms: Calcium deposits under the skin, Raynaud’s, Esophageal reflux, Sclerodactyly (thick skin on fingers), or Telangiectasia (red spots from dilated vessels).

Factors Influencing the Result

• Diagnostic Pattern: On a standard FANA (ANA) test, these antibodies produce a very distinct “centromere pattern” (dozens of bright dots within the nucleus), which is almost diagnostic on its own.
• Prognostic Value: Patients with positive ACA are less likely to develop severe lung fibrosis compared to those with Sci-70, but they have a higher risk of developing Pulmonary Arterial Hypertension (high pressure in the lung arteries) later in life.
• Longevity: These antibodies often appear years, or even decades, before the skin begins to thicken.

When to Take This Test?

• Recommendations: If you have Raynaud’s phenomenon (fingers changing color in the cold) for many years; if you have difficulty swallowing; or if you notice small red “spider” veins on your face or hands.
• Importance: Distinguishing between “Limited” and “Diffuse” scleroderma is vital for predicting the course of the disease and knowing which internal organs need the most monitoring.

Medical Interpretation

• Crucial Note: A positive ACA result often indicates a better skin prognosis than other scleroderma markers. Only a specialist can “fine-tune” your care by monitoring for long-term complications like high blood pressure in the lungs.
• Positive Result: Strongly associated with Limited Systemic Sclerosis (CREST).
• Negative Result: Does not rule out scleroderma; the patient might have the diffuse form (Sci-70 positive) or be “antibody negative.”

Possible Further Investigations

• Nailfold Capillaroscopy: To check for specific changes in the blood vessels at the base of the fingernails.
• Echocardiogram: To monitor the pressure in the heart and lung arteries (essential for ACA-positive patients).
• Pulmonary Function Tests (PFTs): To check for both lung capacity and gas exchange (DLCO).
• Barium Swallow or Endoscopy: To evaluate esophageal involvement if there is chronic reflux.
• Consultation with a Rheumatologist.

When Does the Next Step Make Sense?

• If the Anti-Centromere test is positive, the next step is usually a baseline echocardiogram to check heart and lung pressures. Because the “Limited” form progresses slowly, regular long-term follow-ups are key to catching complications before they cause symptoms.
• All clinical decisions must be made by a healthcare professional based on the physical presentation of skin and vascular changes.

👉 If necessary, you can discuss the analysis results with a specialist such as a rheumatologist (Doctors – TAMC).